2. Search Result
Search Result
Pathways Recommended: Metabolic Enzyme/Protease
Results for "

cardiovascular metabolic diseases

" in MedChemExpress (MCE) Product Catalog:

660

Inhibitors & Agonists

9

Screening Libraries

4

Fluorescent Dye

6

Biochemical Assay Reagents

48

Peptides

9

Inhibitory Antibodies

182

Natural
Products

71

Isotope-Labeled Compounds

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148505
    5'-ODMT cEt N-Bzm5 C Phosphoramidite (Amidite)

    		Nucleoside Antimetabolite/Analog Infection Cardiovascular Disease Metabolic Disease
    5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite is a potent nucleic acid analog. 5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite blongs to modified antisense oligonucleotide. 5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite allows the formation of a specific conformation of the furanose ring of the oligonucleotide through the introduction of a cEt modification, enhancing the ability to hybridize to complementary RNA. 5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite is mainly used in the research of regulation of gene expression related to metabolic diseases, cardiovascular diseases, cancers and the development of antisense compounds .
    5'-ODMT cEt N-Bzm5 C Phosphoramidite (Amidite)
  • HY-125990
    SLC13A5-IN-1

    		Sodium Channel Cardiovascular Disease Metabolic Disease
    SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of  14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5 .
    SLC13A5-IN-1
  • HY-W001171
    3-Hydroxyanthranilic acid
    1 Publications Verification

    		 Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    3-Hydroxyanthranilic acid is a tryptophan metabolite in the kynurenine pathway.3-hydroxyanthranilic acid has anti-inflammatory, neuroprotective, and lipid-lowering effects. 3-hydroxyanthranilic acid can be used for researches of cardiovascular diseases, tumors, and metabolic diseases .
    3-Hydroxyanthranilic acid
  • HY-163358
    SLC3037
    1 Publications Verification

    		 NOD-like Receptor (NLR) NEKs Cardiovascular Disease Neurological Disease Inflammation/Immunology
    SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases .
    SLC3037
  • HY-134325
    8-OH-cAMP

    8-Hydroxy-cAMP

    		 PKA Cardiovascular Disease Metabolic Disease
    8-OH-cAMP (8-Hydroxy-cAMP) is a polar, membrane-impermeable cyclic adenosine monophosphate analog that is resistant to mammalian cyclic nucleotide-dependent phosphodiesterases. As a polar PKA agonist, 8-OH-cAMP is used to study the role of cAMP in the development and progression of cardiovascular and metabolic diseases .
    8-OH-cAMP
  • HY-146731
    PPARγ agonist 1

    		PPAR Cardiovascular Disease Metabolic Disease
    PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .
    PPARγ agonist 1
  • HY-151616
    sEH inhibitor-10

    		Epoxide Hydrolase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    sEH inhibitor-10 (Compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC50=0.5 μM). sEH inhibitor-10 maintains high cycloeicosatrienoic acid (EETs) levels by inhibiting sEH, thereby reducing inflammation, regulating endothelial tone, improving mitochondrial function, and reducing oxidative stress. sEH inhibitor-10 has good research potential in metabolic, renal and cardiovascular diseases .
    sEH inhibitor-10
  • HY-172836S
    GLP-1 receptor agonist 17-d3

    		GCGR Cardiovascular Disease
    GLP-1 receptor agonist 17-d3 (Compound 701) is the deuterium labeled GLP-1R agonist 17 (HY-148212). GLP-1R agonist 17 is a GLP-1 receptor agonist that can be used for the research of cardiovascular metabolic diseases .
    GLP-1 receptor agonist 17-d3
  • HY-160168
    BTK-IN-31

    		Btk Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders .
    BTK-IN-31
  • HY-137608
    Uridine 5'-O-thiodiphosphate

    UDP-β-S

    		 P2Y Receptor Cardiovascular Disease
    Uridine 5'-O-thiodiphosphate (UDP-β-S) is a stable analog of UDP. As a selective agonist of P2Y6 receptor, Uridine 5'-O-thiodiphosphate has higher metabolic stability and can be used in the study of cardiovascular diseases .
    Uridine 5'-O-thiodiphosphate
  • HY-N8630
    Oleacein

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Metabolic Disease
    Oleacein (Compound 9) is an ACE inhibitor that can be isolated from J. grandiflorum. Oleacein is orally active and can be used in the study of metabolic and cardiovascular diseases .
    Oleacein
  • HY-17403
    Manidipine dihydrochloride

    CV-4093

    		 Calcium Channel NF-κB Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Manidipine dihydrochloride is a third-generation, lipophilic, orally active and highly vasoselective calcium channel antagonist (IC50 = 2.6 nM in guinea-pig ventricular cells) and acts as an antihypertensive agent. Manidipine effectively reduces blood pressure as well as improving insulin sensitivity, renal protection, and antiatherosclerotic activity. Manidipine also exerts anti-inflammatory activity mediated by NF-κB and antiviral activity against many flavivirus and negative-strand RNA viruses through the inhibition of calcium channel. Manidipine is widely applied to research of cardiovascular, metabolic disease and infection .
    Manidipine dihydrochloride
  • HY-106938
    Eldacimibe

    WAY-ACA 147

    		 Acyltransferase Cardiovascular Disease Metabolic Disease
    Eldacimibe is an ACAT2 inhibitor. Eldacimibe can lower plasma cholesterol levels by blocking cholesterol absorption and can prevent macrophages from turning into foam cells. Eldacimibe can be used in the study of cardiovascular diseases (atherosclerosis), endocrine and metabolic diseases (hypercholesterolemia) .
    Eldacimibe
  • HY-B2219
    Stearic acid
    10+ Cited Publications

    		 Endogenous Metabolite Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    Stearic acid is a long-chain dietary saturated fatty acid that can significantly reduce visceral fat by inducing apoptosis of preadipocytes. Stearic acid can be used in the study of cardiovascular and metabolic diseases .
    Stearic acid
  • HY-121448
    GW409544

    		PPAR Cardiovascular Disease Metabolic Disease
    GW409544 is a potent PPARα and PPARγ activator, with EC50 values of 2.3 nM and 0.28 nM for PPARα and PPARγ, respectively. GW409544 can be used for the research of metabolic and cardiovascular diseases .
    GW409544
  • HY-14753
    Rosonabant

    		Cannabinoid Receptor Cardiovascular Disease Metabolic Disease
    Rosonabant is a selective antagonist for cannabinoid receptor (CB1 receptor), which reduces body weight and improves improves the risk of obesity-related cardiovascular metabolic diseases. Rosonabant exhibits adverse side effect, such as nausea and mental disorder .
    Rosonabant
  • HY-B1189
    Meglutol

    Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid

    		 HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .
    Meglutol
  • HY-B2219R
    Stearic acid (Standard)
    10+ Cited Publications

    		 Endogenous Metabolite Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    Stearic acid (Standard) is the analytical standard of Stearic acid. This product is intended for research and analytical applications. Stearic acid is a long-chain dietary saturated fatty acid that can significantly reduce visceral fat by inducing apoptosis of preadipocytes. Stearic acid can be used in the study of cardiovascular and metabolic diseases .
    Stearic acid (Standard)
  • HY-115688
    TXNIP-IN-1
    1 Publications Verification

    		 Arrestin Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    TXNIP-IN-1 is TXNIP-TRX (thioredoxin-interacting protein- thioredoxin) complex inhibitor extracted from patent US20200085800A1, Compound 1. TXNIP-IN-1 can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease .
    TXNIP-IN-1
  • HY-148212
    GLP-1R agonist 17

    		GCGR Cardiovascular Disease Metabolic Disease
    GLP-1R agonist 17 is a GLP-1 receptor agonist. GLP-1R agonist 17 shows excellent agonism on a GLP-1 receptor. GLP-1R agonist 17 can be used for the research of cardiovascular metabolic diseases .
    GLP-1R agonist 17
  • HY-103462
    TC-F2

    		FAAH Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .
    TC-F2
  • HY-133890
    Tauro-α-muricholic acid

    T-α-MCA

    		 Endogenous Metabolite FXR Cardiovascular Disease Others Metabolic Disease
    Tauro-alpha-muricholic acid (T-alpha-MCA) is a bile acid that belongs to a class of compounds that are synthesized in the liver and play an important role in the digestive process. Tauro-α-muricholic acid activates Farni X receptors (FXR) which are involved in the regulation of bile acid synthesis, metabolism and transport. Tauro-alpha-muricholic acid can be used in the study of metabolic syndrome and cardiovascular disease .
    Tauro-α-muricholic acid
  • HY-158024A
    (S)-NDT-19795

    		NOD-like Receptor (NLR) Cardiovascular Disease Others Neurological Disease Metabolic Disease Inflammation/Immunology
    (S)-NDT-19795 is a potent NLRP3 inflammasome inhibitor. (S)-NDT-19795 blocks NLRP3 activation by inhibiting NLRP3 ATPase activity, thereby reducing the levels of pro-inflammatory cytokines IL-1β and IL-18. (S)-NDT-19795 can be used in the study of neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and autoimmune diseases .
    (S)-NDT-19795
  • HY-163174
    II399

    		Amine N-methyltransferase Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    II399 is a potent, selective NNMT bisubstrate inhibitor containing an unconventional SAM mimic, with a Ki of 5.9 nM. II399 exhibits an explicit pattern of competitive inhibition for NAM. II399 occupies both the substrate and cofactor binding pockets. II399 has the potential for the research of cancers, metabolic, cardiovascular, and neurodegenerative diseases .
    II399
  • HY-W018026
    Oxfenicine

    L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842

    		 Acyltransferase Apoptosis Cardiovascular Disease Metabolic Disease
    Oxfenicine (L-p-Hydroxyphenylglycine) is an orally active carnitine palmitoyltransferase-1 inhibitor. Oxfenicine inhibits the oxidation of fatty acids in the heart, protecting cardiac tissue from necrotic damage during ischemia, and also has an inhibitory effect on cardiac tissue apoptosis. In addition, Oxfenicine promotes lipolysis in a high-fat diet rat model. Oxfenicine can be used in the study of cardiovascular and metabolic diseases .
    Oxfenicine
  • HY-N2581
    Phytic acid sodium salt
    1 Publications Verification

    myo-Inositol, hexakis(dihydrogen phosphate) sodium salt; Inositol hexaphosphate sodium salt

    		 Endogenous Metabolite Amyloid-β Autophagy Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Phytic acid sodium salt (myo-Inositol; hexakis dihydrogen phosphate; Inositol hexaphosphate) is an orally active compound derived from the seeds of legumes. Phytic acid sodium salt is a [PO4] 3- storage depot and precursor for other inositol phosphates and pyrophosphates. phytic acid is hydrolyzed by phytases in a stepwise manner in the plant. Phytic acid sodium salt attenuates Aβ oligomers and upregulates autophagy protein. Phytic acid sodium salt can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research .
    Phytic acid sodium salt
  • HY-P4153
    Enlicitide chloride

    MK-0616 chloride

    		 PCSK9 Cardiovascular Disease
    Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders .
    Enlicitide chloride
  • HY-119497
    SB251023

    		Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    SB251023 is a β3-adrenergic receptor agonist with pEC50 values of 7.14 and 6.91 for the β3a- and β3b-adrenergic receptors, respectively. SB251023 is capable of modulating cyclic AMP levels and extracellular acidification rate (EAR) in cells. It has potential application value in the study of cardiovascular diseases and metabolic-related disorders .
    SB251023
  • HY-150508
    MK-0159

    		CD38 Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD + (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart .
    MK-0159
  • HY-N9246
    4'-Methoxyflavanone

    		Others Others
    4'-Methoxyflavanone is a flavonoid compound. 4'-Methoxyflavanone is isolated from the natural Isaria fumosorosea KCH J2. 4'-Methoxyflavanone regulates metabolic disorders, prevents cardiovascular disease and protects neurons .
    4'-Methoxyflavanone
  • HY-115688A
    (S)-TXNIP-IN-1
    1 Publications Verification

    		 Arrestin Cardiovascular Disease Others
    (S)-TXNIP-IN-1 is the less active S-enantiomer of TXNIP-IN-1 (HY-115688). TXNIP-IN-1 is a TXNIP-TRX complex inhibitor which can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease
    (S)-TXNIP-IN-1
  • HY-157665
    HSD17B13-IN-39

    		17β-HSD Metabolic Disease
    HSD17B13-IN-39 (Compound A) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-39 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
    HSD17B13-IN-39
  • HY-157664
    HSD17B13-IN-38

    		17β-HSD Metabolic Disease
    HSD17B13-IN-38 (Compound D) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
    HSD17B13-IN-38
  • HY-128145
    HSD17B13-IN-41

    		17β-HSD Metabolic Disease
    HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .
    HSD17B13-IN-41
  • HY-A0241R
    Dalfopristin (Standard)

    		Bacterial Antibiotic Infection
    Stearic acid (Standard) is the analytical standard of Stearic acid. This product is intended for research and analytical applications. Stearic acid is a long-chain dietary saturated fatty acid that can significantly reduce visceral fat by inducing apoptosis of preadipocytes. Stearic acid can be used in the study of cardiovascular and metabolic diseases .
    Dalfopristin (Standard)
  • HY-163263
    HSD17B13-IN-80

    		17β-HSD Metabolic Disease
    HSD17B13-IN-80 (Compound 151) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-80
  • HY-162207
    HSD17B13-IN-54

    		17β-HSD Metabolic Disease
    HSD17B13-IN-54 (Compound 158) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-54 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-54
  • HY-163243
    HSD17B13-IN-29

    		17β-HSD Metabolic Disease
    HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-29
  • HY-163249
    HSD17B13-IN-49

    		17β-HSD Metabolic Disease
    HSD17B13-IN-49 (Compound 81) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-49 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-49
  • HY-161229
    HSD17B13-IN-69

    		17β-HSD Metabolic Disease
    HSD17B13-IN-69 (Compound 11) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-69 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-69
  • HY-162213
    HSD17B13-IN-86

    		17β-HSD Metabolic Disease
    HSD17B13-IN-86 (Compound 188) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-86 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-86
  • HY-163251
    HSD17B13-IN-52

    		17β-HSD Metabolic Disease
    HSD17B13-IN-52 (Compound 84) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-52 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-52
  • HY-163261
    HSD17B13-IN-66

    		17β-HSD Metabolic Disease
    HSD17B13-IN-66 (Compound 146) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-66 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-66
  • HY-162210
    HSD17B13-IN-65

    		17β-HSD Metabolic Disease
    HSD17B13-IN-65 (Compound 168) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-65 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-65
  • HY-161230
    HSD17B13-IN-75

    		17β-HSD Metabolic Disease
    HSD17B13-IN-75 (Compound 21) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-75 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-75
  • HY-162209
    HSD17B13-IN-63

    		17β-HSD Metabolic Disease
    HSD17B13-IN-63 (Compound 160) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-63 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-63
  • HY-163254
    HSD17B13-IN-57

    		17β-HSD Metabolic Disease
    HSD17B13-IN-57 (Compound 93) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-57 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-57
  • HY-163264
    HSD17B13-IN-81

    		17β-HSD Metabolic Disease
    HSD17B13-IN-81 (Compound 154) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-81 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-81
  • HY-157662
    HSD17B13-IN-33

    		17β-HSD Metabolic Disease
    HSD17B13-IN-33 (Compound 115) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-33 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-33
  • HY-163252
    HSD17B13-IN-53

    		17β-HSD Metabolic Disease
    HSD17B13-IN-53 (Compound 88) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-53 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .
    HSD17B13-IN-53

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: